VYGR Voyager Therapeutics Inc
Price (delayed)
$3.41
Market cap
$188.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.13
Enterprise value
$157.74M
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation
Highlights
Voyager Therapeutics's quick ratio has decreased by 34% from the previous quarter but it has increased by 11% YoY
VYGR's equity is up by 27% year-on-year but it is down by 9% since the previous quarter
Voyager Therapeutics's net income has shrunk by 149% YoY
Voyager Therapeutics's EPS has plunged by 137% YoY
Key stats
What are the main financial stats of VYGR
Market
Valuations
Earnings
Shares outstanding
55.21M
Market cap
$188.26M
Enterprise value
$157.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
2.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.97
Revenue
$80M
Gross profit
$80M
Operating income
-$83.29M
Net income
-$65M
EBIT
-$64.34M
EBITDA
-$59.61M
Free cash flow
-$18.83M
Per share
Balance sheet
Liquidity
EPS
-$1.13
EPS diluted
-$1.13
Free cash flow per share
-$0.33
Book value per share
$5.49
Revenue per share
$1.39
TBVPS
$6.82
Total assets
$393.05M
Total liabilities
$93.29M
Debt
$43.73M
Equity
$299.76M
Working capital
$227.02M
Debt to equity
0.15
Current ratio
5.56
Quick ratio
5.46
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-74.5%
Gross margin
100%
Net margin
-81.3%
Operating margin
-104.1%
Return on assets
-15.1%
Return on equity
-19.9%
Return on invested capital
-22.3%
Return on capital employed
-18.7%
Return on sales
-80.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYGR stock price
How has the Voyager Therapeutics stock price performed over time
Intraday
1.19%
1 week
-6.32%
1 month
-16.42%
1 year
-65.59%
YTD
-39.86%
QTD
0.89%
Financial performance
How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$80M
Gross profit
$80M
Operating income
-$83.29M
Net income
-$65M
Gross margin
100%
Net margin
-81.3%
The operating income has dropped by 168% year-on-year
Voyager Therapeutics's net income has shrunk by 149% YoY
VYGR's gross profit has dropped by 68% year-on-year and by 51% since the previous quarter
The revenue has dropped by 68% year-on-year and by 51% since the previous quarter
Growth
What is Voyager Therapeutics's growth rate over time
Valuation
What is Voyager Therapeutics stock price valuation
P/E
N/A
P/B
0.62
P/S
2.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.97
Voyager Therapeutics's EPS has plunged by 137% YoY
VYGR's price to book (P/B) is 72% lower than its 5-year quarterly average of 2.2 and 49% lower than its last 4 quarters average of 1.2
VYGR's equity is up by 27% year-on-year but it is down by 9% since the previous quarter
The revenue has dropped by 68% year-on-year and by 51% since the previous quarter
VYGR's price to sales (P/S) is 31% less than its 5-year quarterly average of 3.5 and 31% less than its last 4 quarters average of 3.5
Efficiency
How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's return on assets has shrunk by 137% YoY
VYGR's return on equity has dropped by 131% year-on-year
Voyager Therapeutics's ROIC has plunged by 120% YoY
Dividends
What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYGR.
Financial health
How did Voyager Therapeutics financials performed over time
VYGR's current ratio is down by 34% since the previous quarter but it is up by 12% year-on-year
Voyager Therapeutics's quick ratio has decreased by 34% from the previous quarter but it has increased by 11% YoY
The company's debt is 85% lower than its equity
The company's debt has surged by 115% YoY
VYGR's debt to equity has soared by 67% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.